Clinical Trial Update: A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating rosuvastatin 20 mg on carotid intima-media thickness in Chinese subjects with subclinical atherosclerosis completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis

Drugs mentioned

• Rosuvastatin (rosuvastatin)

Snippet

Sponsor: AstraZeneca | Conditions: Atherosclerosis | Phase 3 | Status: COMPLETED | Results posted: 2019-12-11